FCGR3B and peripheral arterial disease: In this context, we also observed that several months after the initiation of immunoglobulin replacement treatment, PAD patients display an increase in the expression of CD11b integrin molecule as well as of CD16 on PMN, after LPS incubation, which is also indicative of their enhanced activation capacity after treatment.